TipRanks
Baird Medical Investment Holdings (BDMD)
NASDAQ:BDMD
US Market
Want to see BDMD full AI Analyst Report?

Baird Medical Investment Holdings (BDMD) AI Stock Analysis

73 Followers

Top Page

BDMD

Baird Medical Investment Holdings

(NASDAQ:BDMD)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - Gpt-5.6Sol)
Rating:44Neutral
Price Target:
$0.82
▼(-30.93% Downside)
Action:Reiterated
Date:09/22/26
The score is held down primarily by deteriorating financial performance (sharp revenue decline, swing to losses) and persistently negative operating/free cash flow, which raises funding risk. Technicals add further pressure as the stock remains in a strong downtrend with negative MACD and weak momentum. Valuation provides limited offset because negative earnings make P/E less meaningful and there is no dividend yield support.
Positive Factors
2026 Revenue and Profit Recovery
The first-half 2026 rebound indicates that international expansion and licensing activity can restore growth after the prior-year downturn. A return to positive earnings, even at a modest level, improves operating resilience and provides a foundation for rebuilding profitability.
Negative Factors
Persistently Negative Cash Generation
Repeatedly negative operating and free cash flow shows that reported business activity has not yet translated into internally funded operations. If this persists, the company may need external capital to support commercialization, increasing funding dependence and reducing financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
2026 Revenue and Profit Recovery
The first-half 2026 rebound indicates that international expansion and licensing activity can restore growth after the prior-year downturn. A return to positive earnings, even at a modest level, improves operating resilience and provides a foundation for rebuilding profitability.
Read all positive factors

Baird Medical Investment Holdings (BDMD) vs. SPDR S&P 500 ETF (SPY)

Baird Medical Investment Holdings Business Overview & Revenue Model

Company Description
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive manage...

Baird Medical Investment Holdings Financial Statement Overview

Summary
Financials are pressured: 2025 revenue fell ~29% YoY and results swung from profitability to a deep operating loss and net loss. Cash flow is a major weakness with negative operating cash flow in 2023–2025 and negative free cash flow in 2022–2025, increasing reliance on external funding. The balance sheet is somewhat supportive (debt ~0.62x equity), but equity declined and continued losses could erode flexibility.
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue24.49M22.54M37.04M31.46M35.09M27.72M
Gross Profit20.97M18.88M32.65M27.23M28.04M23.18M
EBITDA-13.02M-24.53M16.17M12.88M16.29M14.16M
Net Income-15.97M-27.28M12.45M10.55M12.57M11.68M
Balance Sheet
Total Assets73.85M69.70M77.96M56.71M42.62M26.12M
Cash, Cash Equivalents and Short-Term Investments289.08K178.32K2.97M1.63M1.91M3.44M
Total Debt14.22M19.30M20.88M9.90M7.44M2.93M
Total Liabilities39.22M38.48M38.20M21.00M16.84M10.26M
Stockholders Equity34.77M31.37M39.66M35.75M25.93M5.20M
Cash Flow
Free Cash Flow1.85M-1.39M-9.17M-3.66M-5.47M3.87M
Operating Cash Flow1.85M-1.34M-6.31M-1.02M485.97K5.26M
Investing Cash Flow2.29K-42.31K-2.85M-2.64M-5.92M-1.39M
Financing Cash Flow-3.59M-1.39M10.72M3.46M4.41M-1.93M

Baird Medical Investment Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.18
Price Trends
50DMA
1.09
Negative
100DMA
1.23
Negative
200DMA
1.44
Negative
Market Momentum
MACD
-0.07
Positive
RSI
23.79
Positive
STOCH
25.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDMD, the sentiment is Negative. The current price of 1.18 is above the 20-day moving average (MA) of 1.06, above the 50-day MA of 1.09, and below the 200-day MA of 1.44, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 23.79 is Positive, neither overbought nor oversold. The STOCH value of 25.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDMD.

Baird Medical Investment Holdings Risk Analysis

Baird Medical Investment Holdings disclosed 83 risk factors in its most recent earnings report. Baird Medical Investment Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Baird Medical Investment Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$114.56M-3.51-191.05%――19.38%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
46
Neutral
$124.27M-14.27-78.70%―25.59%55.35%
46
Neutral
$6.68M-0.28-174.26%―41.62%20.47%
44
Neutral
$33.35M-1.44-48.29%―――
44
Neutral
$49.66M-4.56-23.45%―-14.27%-132.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BDMD
Baird Medical Investment Holdings
0.79
-1.63
-67.36%
APYX
Apyx Medical
2.95
0.90
43.90%
VANI
Vivani Medical
1.23
-0.24
-16.33%
XTNT
Xtant Medical Holdings
0.38
-0.25
-40.19%
ICCM
Icecure Medical
1.87
-29.63
-94.06%

Baird Medical Investment Holdings Corporate Events

Baird Medical Swings to Profit on 25% Revenue Surge in First Half of 2026
Sep 3, 2026
On September 3, 2026, Baird Medical reported preliminary unaudited financial results for the six months ended June 30, 2026, showing that revenue rose 24.6% year over year to about $9.9 million, driven largely by sales growth outside the PRC, part...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 22, 2026